Drug evaluation: The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom?

Dragana Nikolic, Khalid Al-Rasadi

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of this combination therapy is still limited due to persistent controversy with respect to clinical trial outcomes and safety issues. The available evidence supports fenofibrate/simvastatin therapy as a viable treatment for mixed dyslipidemia. It seems to be particularly beneficial in subjects with high triglycerides and low high-density lipoprotein cholesterol, including subjects with type 2 diabetes (T2DM). However, larger prospective studies are needed to better quantitate the effect of this combination therapy on CVD morbidity and mortality of T2DM subjects as well as nondiabetic patients with mixed dyslipidemia.

Original languageEnglish
Title of host publicationCombination Therapy In Dyslipidemia
PublisherSpringer International Publishing
Pages179-190
Number of pages12
ISBN (Print)9783319204338, 9783319204321
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Fenofibrate
Drug Evaluation
Simvastatin
Dyslipidemias
Therapeutics
Multiple Abnormalities
Lipids
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug Combinations
Hyperlipidemias
LDL Cholesterol
Type 2 Diabetes Mellitus
HDL Cholesterol
Triglycerides
Cholesterol
Clinical Trials
Prospective Studies
Morbidity
Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Drug evaluation : The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom? / Nikolic, Dragana; Al-Rasadi, Khalid.

Combination Therapy In Dyslipidemia. Springer International Publishing, 2015. p. 179-190.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nikolic, Dragana ; Al-Rasadi, Khalid. / Drug evaluation : The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom?. Combination Therapy In Dyslipidemia. Springer International Publishing, 2015. pp. 179-190
@inbook{2252509bbfdf49f59c6151aec3a7d2e4,
title = "Drug evaluation: The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom?",
abstract = "Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of this combination therapy is still limited due to persistent controversy with respect to clinical trial outcomes and safety issues. The available evidence supports fenofibrate/simvastatin therapy as a viable treatment for mixed dyslipidemia. It seems to be particularly beneficial in subjects with high triglycerides and low high-density lipoprotein cholesterol, including subjects with type 2 diabetes (T2DM). However, larger prospective studies are needed to better quantitate the effect of this combination therapy on CVD morbidity and mortality of T2DM subjects as well as nondiabetic patients with mixed dyslipidemia.",
author = "Dragana Nikolic and Khalid Al-Rasadi",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/9783319204338_15",
language = "English",
isbn = "9783319204338",
pages = "179--190",
booktitle = "Combination Therapy In Dyslipidemia",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Drug evaluation

T2 - The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom?

AU - Nikolic, Dragana

AU - Al-Rasadi, Khalid

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of this combination therapy is still limited due to persistent controversy with respect to clinical trial outcomes and safety issues. The available evidence supports fenofibrate/simvastatin therapy as a viable treatment for mixed dyslipidemia. It seems to be particularly beneficial in subjects with high triglycerides and low high-density lipoprotein cholesterol, including subjects with type 2 diabetes (T2DM). However, larger prospective studies are needed to better quantitate the effect of this combination therapy on CVD morbidity and mortality of T2DM subjects as well as nondiabetic patients with mixed dyslipidemia.

AB - Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of this combination therapy is still limited due to persistent controversy with respect to clinical trial outcomes and safety issues. The available evidence supports fenofibrate/simvastatin therapy as a viable treatment for mixed dyslipidemia. It seems to be particularly beneficial in subjects with high triglycerides and low high-density lipoprotein cholesterol, including subjects with type 2 diabetes (T2DM). However, larger prospective studies are needed to better quantitate the effect of this combination therapy on CVD morbidity and mortality of T2DM subjects as well as nondiabetic patients with mixed dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=84955328935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955328935&partnerID=8YFLogxK

U2 - 10.1007/9783319204338_15

DO - 10.1007/9783319204338_15

M3 - Chapter

AN - SCOPUS:84955328935

SN - 9783319204338

SN - 9783319204321

SP - 179

EP - 190

BT - Combination Therapy In Dyslipidemia

PB - Springer International Publishing

ER -